Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The c-MET proto-oncogene (MET) is implicated in lung oncogenesis, influencing cancer cell survival, growth, and invasiveness.
• MET receptor dysregulation is a significant factor in non-small-cell lung cancer (NSCLC), presenting a therapeutic target.
• Next-generation sequencing facilitates the identification of MET pathway anomalies, including MET exon-14 (METex14) skipping mutations.

Purpose of the Study:

• To review laboratory findings on MET and its anomalies.
• To summarize clinical trial results for METex14 alterations and MET amplification in NSCLC.
• To discuss acquired resistance to tyrosine-kinase inhibitors (TKIs) in EGFR-mutated NSCLCs.

Main Methods:

• Literature review of laboratory findings on MET.
• Analysis of clinical trial data for MET alterations in NSCLC.
• Review of resistance mechanisms in EGFR-mutated NSCLC treated with TKIs.

Main Results:

• Early trials with anti-MET agents in unselected or MET-overexpressing NSCLC patients yielded disappointing outcomes.
• Tumors with MET exon-14 alterations represent a promising context for anti-MET therapies.
• MET amplification confers resistance to EGFR TKIs in EGFR-mutated NSCLCs, suggesting a role for anti-MET agents.

Conclusions:

• MET exon-14 alterations and MET amplification in EGFR-mutated NSCLCs are key scenarios for effective anti-MET agent utilization.
• MET-targeted therapies hold potential for specific NSCLC patient subgroups, particularly those with METex14 mutations or acquired resistance to EGFR TKIs.
• Further research is warranted to optimize anti-MET strategies in NSCLC treatment.